Company Overview and News

0
Duterte Has Grand Ambitions to Share Manila's Wealth - Bloomberg

2018-07-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MMTOY TM 7203 TYT TOYOF 7211 MMTOF

0
Vehicle sales seen rising by 12%

2018-07-11 business.inquirer.net
The volume of vehicles sold in the Philippines is primed for a 12-percent growth this year to reach about 577,000 units amid a government drive to upgrade jeepneys and increase in domestic production, according to Frost & Sullivan.
MMTOY TM 7203 TYT TOYOF 7211 MMTOF

0
Nissan Falsifies Exhaust Emission Data in New Issue for Saikawa - Bloomberg

2018-07-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
5406 VLKAF KBSTF MMTOY KBSTY 7269 DDAIF 7211 MMTOF

0
Nissan Says It Found ‘Misconduct' in Exhaust, Fuel Economy Tests - Bloomberg

2018-07-09 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
5406 VLKAF KBSTF MMTOY KBSTY 7269 7211 MMTOF

0
Nissan says it found ‘misconduct’ in exhaust, fuel economy tests

2018-07-09 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
5406 VLKAF KBSTF MMTOY KBSTY 7269 7211 MMTOF

0
Death Toll Rises to 54 as `Historic' Floods Continue in Japan - Bloomberg

2018-07-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
7261 PCRFY MZDAY TM TYT TOYOF MMTOY MZDAF 9437 7203 NTDMF 7211 MMTOF DCM

0
At least 49 killed, 48 missing as torrential rain pounds Japan

2018-07-07 channelnewsasia
TOKYO: Forty nine people have been killed and 48 are unaccounted for in western and central Japan as torrential rain pounds the area, public broadcaster NHK said on Saturday, with more than 1.6 million evacuated from their homes.
7261 MMTOY MZDAY MZDAF 7211 MMTOF

0
At least 27 killed, 47 missing as torrential rain pounds Japan - Channel NewsAsia

2018-07-07 channelnewsasia
TOKYO: At least 47 people were missing and five were in a critical condition as torrential rain that has killed 27 people pounds western and central Japan, public broadcaster NHK said on Saturday, with more than 1.6 million people evacuated from their homes.
7261 MMTOY MZDAY MZDAF 7211 MMTOF

0
Renault and Nissan eye possible merger within two years: sources

2018-07-05 japantimes.co.jp
Renault SA and Nissan Motor Co. have given themselves two years to decide on a possible merger or find an alternative mechanism to enhance their partnership, people familiar with the matter said.
MMTOY RNO 7211 MMTOF

0
Renault and Nissan set two-year target to boost alliance

2018-07-05 malaymail
TOKYO, July 5 — Renault SA and Nissan Motor Co have given themselves two years to decide on a possible merger between the two automakers or find an alternative mechanism to enhance their partnership, people familiar with the matter said.
MMTOY RNO 7211 MMTOF

0
Renault and Nissan set two-year target to boost alliance

2018-07-04 theedgemarkets
TOKYO (July 4): Renault SA and Nissan Motor Co have given themselves two years to decide on a possible merger between the two automakers or find an alternative mechanism to enhance their partnership, people familiar with the matter said.
MMTOY RNO 7211 MMTOF

0
Renault, Nissan said to target two years to boost alliance

2018-07-04 malaymail
TOKYO, July 4 — Renault SA and Nissan Motor Co have given themselves two years to decide on a possible merger between the two automakers or find an alternative mechanism to enhance their partnership, people familiar with the matter said.
MMTOY RNO 7211 MMTOF

21
Japan’s automakers chase IT tie-ups in race for driving’s future

2018-06-28 japantimes.co.jp
Facing what has been touted as a once-in-a-century transformation, domestic carmakers are rushing to transition from conventional manufacturers into tech-driven “mobility companies” focused on CASE (connected, autonomous, shared and electric) technologies.
7261 MZDAY TM TYT GOOG TOYOF RNO MMTOY GOOGL GM.WS.A GM.WS.B MZDAF GM.WS.C 7203 GM GM.WSB 7211 MMTOF

16
Nikkei treads water as U.S.-China trade war brews

2018-06-28 japantimes.co.jp
Stocks finished a tad lower Thursday as active buying was held in check by fears of a brewing trade war.
MMTOY TKCBY OCLCF SHWDY SHWDF 7211 MMTOF ORCL

0
Mitsubishi Motors to provide plug-in hybrid technology to Renault

2018-06-27 japantimes.co.jp
Mitsubishi Motors Corp. will provide its plug-in hybrid technology to Renault SA as part of their three-way alliance with Nissan Motor Co., a source said Wednesday.
MMTOY RNO 7211 MMTOF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...